Last reviewed · How we verify
Placebo to valsartan — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to valsartan (Placebo to valsartan) — Novartis. This is a placebo control, not an active drug, and therefore has no pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to valsartan TARGET | Placebo to valsartan | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to valsartan CI watch — RSS
- Placebo to valsartan CI watch — Atom
- Placebo to valsartan CI watch — JSON
- Placebo to valsartan alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to valsartan — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-valsartan. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab